Latest Pharma and Biotech News
Pharmaceutical
27 November 2024 The strain of opioid use disorder (OUD), a chronic neurological disorder characterized by the compulsive, repeated use of opioid drugs, has weighed heavily on many countries in recent years, especially the USA.
Today's issue
Refine Search
Biotechnology
Gastrointestinal diseases specialist RedHill Biopharma has announced the publication of results from treatment of the first severe COVID-19 patients with its investigational drug, opaganib. 24 June 2020
Biotechnology
US neuroscience-focused start-up Yumanity Therapeutics has entered into a strategic research collaboration and license agreement with pharma giant Merck & Co focused on accelerating the development of new treatments for neurodegenerative diseases. 24 June 2020
Biotechnology
Norwegian natural killer cell specialist Zelluna Immunotherapy has agreed terms for a new research collaboration, with Singapore-based Lion TCR. 24 June 2020
Biotechnology
UK-based Kymab has won another court ruling, this time in its home country, in its global patent dispute with US biotech Regeneron. 24 June 2020
Biotechnology
Sunesis Pharmaceuticals has revealed it will not advance its non-covalent BTK inhibitor vecabrutinib into the planned Phase II portion of the Phase Ib/ii trial in adults with relapsed/refractory chronic lymphocytic leukemia (CLL) and other B-cell malignancies. 24 June 2020
Biotechnology
There is good news for oncology specialist Innate Pharma, which has been told by the US regulator that a partial clinical hold on the Phase II TELLOMAK study has been lifted. 24 June 2020
Biotechnology
In a Special Report, Mircea Cubillos, Regional Commercial Strategy Leader, Haematology, Janssen EMEA, reflects on the recent ASCO and EHA congresses. And despite the unprecedented virtual format, he claims the oncology community can come away from both events feeling excited about the future. 24 June 2020
Biotechnology
US biotech Gilead Sciences has announced that it will pay $275 million to acquire a 49.9% equity interest in privately-held Pionyr Immunotherapeutics and an exclusive option to purchase the remainder of the immuno-oncology (I-O) company. 23 June 2020
Biotechnology
Set against a backdrop of fraught Sino-American relations, WuXi NextCODE hopes that a company rebrand will help ensure stability and future growth. 23 June 2020
Biotechnology
The share price of Myovant Sciences was 7% higher minutes ahead of the opening of US markets on Tuesday. 23 June 2020
Biotechnology
Translate Bio, the messenger RNA (mRNA) company, was trading up to 76% higher in pre-trading on Tuesday. 23 June 2020
Biotechnology
Moscow-based drugmaker R-Opra is to break ground on a new manufacturing site at Alabushevo, just outside the Russian capital. 23 June 2020
Biotechnology
Health Canada has authorized Qinlock (ripretinib), a switch-control tyrosine kinase inhibitor, for sale in Canada for the treatment of adult patients with advanced gastrointestinal stromal tumor (GIST). 23 June 2020
Biotechnology
Cell and gene specialist Orgenesis has entered into a preliminary, non-binding term sheet with Leidos to develop and potentially obtain US marketing approval of ranpirnase for the systemic treatment of patients with SARS-CoV-2, the virus that causes COVID-19. 22 June 2020
Biotechnology
Sarepta Therapeutics aims to expand its gene therapy capability via a global research and option agreement with Codiak BioSciences. 22 June 2020
Biotechnology
US immuno-oncology (I-O) focussed biotech Agenus saw its shares advance 6% pre-market today, following the announcement of an out-licensing deal, but lost the gains by mid-morning. 22 June 2020
Biotechnology
French pharma major Sanofi’s investigational enzyme replacement therapy (ERT), avalglucosidase alfa met the primary endpoint demonstrating non-inferiority in improving respiratory muscle strength, as measured by using percent-predicted forced vital capacity (FVC) in the upright position, compared to alglucosidase alfa (standard of care) in patients with late-onset Pompe disease (LOPD). 22 June 2020
Biotechnology
The British biotech industry has released a new report indicating the resilience of the sector under the challenging conditions of the coronavirus pandemic. 22 June 2020
Biotechnology
The European medicines regulator is to review a bid from Germany’s Merck KGaA and New York’s Pfizer to extend the marketable use of Bavencio (avelumab). 22 June 2020
Biotechnology
British cell therapy specialist Rexgenero has bought all the key assets of Paris-based immunotherapy company aratinga.bio, a preclinical-stage firm developing an off-the-shelf CAR-T cell therapy. 22 June 2020
All news
Biotechnology
PTC Therapeutics is to sell its rare pediatric disease priority review voucher (PRV) for $150 million. 28 November 2024
Biotechnology
A report from industry analyst DelveInsight highlights progress in the myotonic dystrophy treatment landscape, with more than 20 companies developing over 22 innovative treatments. 28 November 2024
Biotechnology
The UK subsidiary of Dutch drugmaker argenx confirmed today that its investigational therapy, subcutaneous efgartigimod alfa has been granted Promising Innovative Medicine (PIM) designation by the UK Medicines and Healthcare products Regulatory Agency (MHRA) for the treatment of adults with chronic inflammatory demyelinating polyneuropathy (CIDP). 28 November 2024
Biotechnology
Privately-held French drugmaker Servier has announced the inauguration of its first unit dedicated to the production of biological medicines from its R&D pipeline. 28 November 2024
Biotechnology
The US Food and Drug Administration has received new reports of hematologic malignancies, including life-threatening cases of myelodysplastic syndrome (MDS) and acute myeloid leukemia (AML), following treatment of early, active cerebral adrenoleukodystrophy (CALD) patients with Skysona (elivaldogene autotemcel). 28 November 2024
Biotechnology
San Diago, USA-based Acadia Pharmaceuticals yesterday announced it has entered into an exclusive worldwide license agreement with Denmark’s Saniona for the development and commercialization of SAN711, a first-in-class, highly selective GABAA-α3 positive allosteric modulator. 28 November 2024
Biotechnology
Kronos Bio, a biotech with a presence on the east and west coasts of the USA, has unveiled a major restructuring plan. 28 November 2024
Biotechnology
Johnson & Johnson has made significant strides in multiple myeloma treatment, with breakthroughs in targeted therapies like CAR-T and bispecific antibodies. At the 2024 ASH meeting, J&J aims to showcase progress, with a goal of achieving a functional cure for multiple myeloma. 28 November 2024
Biotechnology
The European medicines regulator has approved a combo therapy starring PD-1 inhibitor Tevimbra (tislelizumab), from cancer firm BeOne Medicines, formerly BeiGene. 27 November 2024
Biotechnology
After trading closed yesterday, Exelixis revealed that the US Food and Drug Administration (FDA) has notified the company that the supplemental New Drug Application (sNDA) for cabozantinib (Cabometyx) for the treatment of adults with previously treated advanced pancreatic neuroendocrine tumors (pNET) and advanced extra-pancreatic NET (epNET) will be discussed at an Oncologic Drugs Advisory Committee (ODAC) meeting in March 2025. 27 November 2024
Biotechnology
Chengdu-based Kelun-Biotech has received marketing authorization in China for sacituzumab tirumotecan (sac-TMT), a Trop2-directed antibody-drug conjugate (ADC). 27 November 2024
Biotechnology
AI-powered protein engineering company Cradle has raised $73 million in a Series B funding. The European firm, which has now raised more than $100 million in total, calls itself the leading platform for AI-powered protein engineering. 27 November 2024
Biotechnology
US clinical stage biotech Alector saw its shares tumble 35% to $2.57 by close of trading yesterday, as it announced disappointing results from the INVOKE-2 Phase II clinical trial evaluating the safety and efficacy of AL002 in slowing disease progression in individuals with early Alzheimer’s disease (AD). 27 November 2024
Biotechnology
PTC Therapeutics has announced that its Phase II trial for utreloxastat, aimed at treating amyotrophic lateral sclerosis (ALS), failed to meet its primary endpoint. 27 November 2024
Biotechnology
US companies Arrowhead Pharmaceuticals and Sarepta Therapeutics have announced a global licensing and collaboration agreement. 26 November 2024
Biotechnology
Clinical-stage US CAR-T therapies developer Poseida Therapeutics saw its shares skyrocket 227% to $9.36 pre-market today, on the news of a proposed takeover by Swiss pharma giant Roche. 26 November 2024
Biotechnology
Replimune, a clinical-stage biotech focused on oncolytic immunotherapies, has announced plans to raise $125 million through a public offering. 26 November 2024
Biotechnology
Chinese gene therapy firm Kanglin Biotechnology has completed a $20 million series A financing round, with the money earmarked for KL003, an innovative treatment for blood disorders. 26 November 2024
Biotechnology
BRL Medicine, a Shanghai-based biotechnology company specializing in cell and gene therapies, has raised nearly 200 million yuan ($27 million) in a series B+ round led by CSPC Fund. 26 November 2024
Biotechnology
Italian oncology focused biotech Nerviano Medical Sciences yesterday announced that it has successfully negotiated with Germany’s Merck KGaA to buy back the full world-wide rights of NMS 293 (also known as NMS-03305293). 26 November 2024
Sign up to receive email updates
Join industry leaders for a daily roundup of biotech & pharma news
Copyright © The Pharma Letter 2024 | Headless Content Management with Blaze